Flagship Pioneering

Etiome is a pioneering biotechnology company that specializes in the development and deployment of innovative medicines, known as Biostaged Medicines. These medicines are designed to map and understand the progression of diseases with unprecedented precision. Etiome's technology enables it to characterize diseases with enhanced resolution over time, allowing for the creation of therapies tailored to specific stages of disease. This approach empowers the healthcare industry to intervene at early disease stages, potentially preventing further progression and improving patient outcomes.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Lila Sciences is a technology company specializing in AI-driven platforms for scientific research. It focuses on life, chemical, and materials sciences, developing tools and autonomous labs to streamline research and facilitate discoveries. The company's platform uses generative AI to process vast amounts of data, design experiments, generate hypotheses, and test them in real-world environments, thereby accelerating scientific breakthroughs and enabling rapid innovation.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Mirai Bio is a biotechnology company that has created an AI-driven, open platform to overcome challenges in the development and manufacturing of genetic medicines. Their platform offers tools for biological and biomedical research, including data compilation, analysis algorithms, and scientific article search, focusing on DNA, RNA, and protein sequence analysis. This enables researchers to efficiently analyze data, derive insights from biological sequences, and accelerate their research progress.

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Alltrna is a biotechnology company focused on understanding tRNA biology and developing therapeutics to address a wide range of diseases. By leveraging its advanced platform, which integrates artificial intelligence and machine learning tools, Alltrna aims to decode the complexities of tRNA, a crucial component in the process of translating mRNA into proteins. This innovative approach allows for the creation of diverse programmable molecules with significant therapeutic potential, enabling the correction of various diseases through targeted interventions. Through its work, Alltrna aspires to expand the possibilities of tRNA-based treatments in the medical field.

Empress Therapeutics is an early-stage biotechnology company focused on drug development and gaining new molecular insights into health and disease. The company utilizes a proprietary bio platform that integrates evolutionary principles, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules. This innovative approach aims to enable clinicians to address a variety of serious unmet medical needs through the development of small-molecule drug candidates.

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Montai Health is dedicated to improving health outcomes by harnessing nature's power through advanced digital technology to treat and prevent chronic diseases. The company is focused on developing Anthromolecule medications, which are based on a unique class of compounds with a proven history of safe human use. By creating the world's first Anthromolecule Bioactivity Atlas, Montai Health aims to map the connections to biological pathways associated with various diseases, enabling the rapid and repeatable development of safe and effective treatments. Additionally, the company emphasizes molecular nutrition research to protect and enhance human health sustainably, employing a multidisciplinary approach that incorporates machine learning, big data, multi-omics, and high-throughput screening. This comprehensive strategy positions Montai Health to address global health challenges and improve patient recovery outcomes.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Apriori Bio is a health security company dedicated to protecting humanity from viral threats. It employs a unique technology platform that surveys the landscape of existing and potential viral variants, enabling the design of variant-resilient vaccines and antibody drugs. By providing real-time insights, Apriori Bio aims to prepare for future outbreaks and ensure durable protection against rapidly evolving viruses. The company's innovative approach focuses on developing effective solutions to combat both current and emerging viral challenges.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Vesalius Therapeutics is a biotechnology company dedicated to enhancing the understanding and treatment of diseases responsible for the majority of human illnesses. The company has developed a platform that connects clinical patterns with the interactions of various genes, identifying the genetic circuits that contribute to disease. Additionally, Vesalius creates proprietary patient-derived, cell-based experimental models that allow for the screening and characterization of drug candidates aimed at restoring these genetic circuits to their healthy states. This innovative approach enables healthcare practitioners to recognize previously unobserved clinical patterns among groups of patients, ultimately aiming to improve treatment outcomes for common illnesses.

Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Alltrna is a biotechnology company focused on understanding tRNA biology and developing therapeutics to address a wide range of diseases. By leveraging its advanced platform, which integrates artificial intelligence and machine learning tools, Alltrna aims to decode the complexities of tRNA, a crucial component in the process of translating mRNA into proteins. This innovative approach allows for the creation of diverse programmable molecules with significant therapeutic potential, enabling the correction of various diseases through targeted interventions. Through its work, Alltrna aspires to expand the possibilities of tRNA-based treatments in the medical field.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Laronde is a biopharmaceutical company that specializes in developing eRNA-based therapeutics designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative platform, known as Endless RNA, is characterized by its persistence, non-immunogenic properties, and adaptability for repeat dosing and various delivery methods. This flexibility positions Laronde to support the simultaneous advancement of multiple therapeutic programs across different disease areas, aiming to create more predictable and impactful medicines for patients. The company's approach seeks to redefine the possibilities of therapeutic development, ultimately contributing to the creation of essential medicines for the future.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a multi-platform technology company headquartered in Cambridge, Massachusetts, with additional offices in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Established in 2016, the company focuses on harnessing advanced sciences to address critical challenges in agriculture, nutrition, and the environment. Invaio's innovative technologies aim to reduce pesticide usage globally by enhancing the understanding of insect physiology and interdependent natural systems. By developing solutions that are both effective against pests and safe for beneficial species, Invaio seeks to create a positive impact on agriculture and human and animal health, positioning itself at the forefront of transformative practices in these fields.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Laronde is a biopharmaceutical company that specializes in developing eRNA-based therapeutics designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative platform, known as Endless RNA, is characterized by its persistence, non-immunogenic properties, and adaptability for repeat dosing and various delivery methods. This flexibility positions Laronde to support the simultaneous advancement of multiple therapeutic programs across different disease areas, aiming to create more predictable and impactful medicines for patients. The company's approach seeks to redefine the possibilities of therapeutic development, ultimately contributing to the creation of essential medicines for the future.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

Ohana Biosciences is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing innovative molecular techniques aimed at enhancing reproductive health, particularly by focusing on sperm biology rather than egg biology. Ohana's products are designed to improve sperm quality and function, thereby addressing infertility and preventing inherited diseases. Additionally, the company is working on a long-acting, reversible, and non-hormonal male contraceptive. Through its advancements in reproductive medicine, Ohana Biosciences aims to empower individuals and couples to have children on their own terms, while also striving to reduce pregnancy complications.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a multi-platform technology company headquartered in Cambridge, Massachusetts, with additional offices in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Established in 2016, the company focuses on harnessing advanced sciences to address critical challenges in agriculture, nutrition, and the environment. Invaio's innovative technologies aim to reduce pesticide usage globally by enhancing the understanding of insect physiology and interdependent natural systems. By developing solutions that are both effective against pests and safe for beneficial species, Invaio seeks to create a positive impact on agriculture and human and animal health, positioning itself at the forefront of transformative practices in these fields.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Cygnal Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing drugs that manipulate exoneural biology to address cancer, immunological diseases, and regenerative processes. Founded in 2016 by Flagship Pioneering within the VentureLabs innovation foundry, Cygnal harnesses advanced neurotechnology to explore and discover new dimensions of neural function. The company aims to create innovative therapeutic options by leveraging its unique approach to understanding and altering the interactions between the nervous system and various biological processes.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Axcella Health Inc., established in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions targeting various biological pathways. The company's pipeline includes AXA1665 for hepatic encephalopathy, AXA1125 and AXA1957 for non-alcoholic steatohepatitis, AXA2678 for muscle atrophy, and AXA4010 for multiple biological pathways.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to understand and manipulate gene expression to develop innovative therapies for various diseases, particularly cancer. Foghorn is advancing several drug candidates, including FHD-286, an enzymatic inhibitor targeting BRG1 and BRM for acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader aimed at treating synovial sarcoma. Additionally, the company has ongoing preclinical and discovery programs targeting non-small-cell lung cancer and other cancers associated with ARID1B mutations. Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to create novel oncology therapeutics. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics is pioneering a new class of drug targets that could transform treatment approaches for patients with serious diseases.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

Inzen Therapeutics is an early-stage biotechnology company focused on developing innovative treatments for chronic diseases. The company investigates cellular turnover as a significant factor in disease progression. Utilizing a platform that integrates mass spectrometry, machine learning, and advanced genetic and chemical biological technologies, Inzen aims to create novel therapeutic products. Its research targets various health conditions, including cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. By leveraging these technologies, Inzen seeks to provide medical practitioners with effective treatment options for complex health issues.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. The company specializes in developing multi-functional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide aimed at crop protection, and BN2266, a fungicide that targets mRNA processing. Additionally, the company is working on a dual-function nematicide-fungicide for root protection and endo-parasiticides designed to overcome resistance. Boragen's innovative synthetic chemistry platform focuses on creating next-generation fungicides that support sustainable farming by minimizing the risk of fungicide resistance and reducing chemical usage while ensuring efficacy and performance.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Incredible Foods, Inc. is a Boston-based manufacturer of non-dairy frozen products sold under the perfectlyfree brand. Established in 2012, the company specializes in creating delicious and allergy-friendly food options, including fruit bites, frozen bites, and frozen pints. Its offerings are designed to be "Big 8 Allergy-Friendly," meaning they do not contain the eight most common allergens: dairy, wheat, peanuts, tree nuts, eggs, soy, fish, and shellfish. All products are made with natural, premium, non-GMO ingredients in a dedicated facility that ensures a safe and allergen-free environment. Incredible Foods aims to enhance the lives of its consumers by providing enjoyable and health-conscious food choices. The company operates as a subsidiary of Quantum Designs, LLC and rebranded from Wikifoods, Inc. in July 2016.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Rubius Therapeutics, Inc. is a biotechnology company focused on developing red cell therapeutics (RCTs) aimed at treating patients with severe diseases, including cancer, enzyme deficiencies, and autoimmune disorders. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. By creating a new class of medicines, Rubius Therapeutics seeks to address significant unmet medical needs through innovative approaches in the field of biotechnology.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Axcella Health Inc., established in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions targeting various biological pathways. The company's pipeline includes AXA1665 for hepatic encephalopathy, AXA1125 and AXA1957 for non-alcoholic steatohepatitis, AXA2678 for muscle atrophy, and AXA4010 for multiple biological pathways.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Joule Unlimited, Inc., established in 2007, specializes in developing technology to produce low-carbon transportation fuels. The company's core process involves using solar energy to convert waste CO2 into renewable fuels, such as ethanol and hydrocarbons suitable for diesel, jet fuel, and gasoline. Joule Unlimited serves a global customer base, with operations in the United States, Europe, Australia, Mexico, and China. Notably, it has a strategic partnership with Audi. The company's products include Sunflow-E, a solar ethanol, and Sunflow-D, a solar diesel. Joule Unlimited is headquartered in Cambridge, Massachusetts, with additional offices in Los Angeles, California, and The Hague, the Netherlands, and production facilities in Hobbs, New Mexico.

Red Rock Biofuels develops processing plants that convert woody biomass into renewable diesel and jet fuels, aiming to address climate change and improve forest health. Each facility is designed to process 175,000 dry tons of woody biomass annually, producing approximately 16 million gallons of finished fuels. The company's proprietary technology involves gasifying woody biomass to generate synthesis gas, which is then cleaned and transformed into liquid hydrocarbons through a Fischer-Tropsch unit. This process is followed by hydroprocessing to refine the hydrocarbons into jet, diesel, and naphtha fuels. By utilizing waste wood biomass, Red Rock Biofuels enables airlines and transportation companies to lower their carbon footprints while promoting sustainable forestry practices. Founded by Jeff Manternach and Terry Kulesa, the company is based in Colorado, United States.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

EcoSense Lighting is a team of LED lighting pioneers with over 100 years of experience and a genuine passion for delivering advanced solid-state lighting solutions. EcoSense delivers a broad line of high-quality, cutting-edge LED lighting solutions for architectural and commercial applications. EcoSense has a compelling technology portfolio including the new industry-leading breakthrough dimming technology. EcoSense has offices in the United States, the United Kingdom, and Hong Kong with headquarters in Los Angeles.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through its expertise in plant microbiomes. By leveraging a database of genomic microbe information, Indigo identifies and applies beneficial microbes to crops, primarily through seed coatings. This approach not only helps optimize plant health and yields but also aims to improve farmer profitability. Additionally, Indigo is committed to addressing broader agricultural challenges by promoting practices that reduce reliance on water, nitrogen fertilizers, and pesticides. Through these innovations, Indigo seeks to better serve the needs of farmers and consumers alike, contributing to the capacity to feed a growing global population while fostering sustainable farming practices.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.